Search results
Results from the WOW.Com Content Network
Huntsman Cancer Institute was founded with a pledge of $100 million of personal wealth from Jon Huntsman Sr., a philanthropist and businessman. To date, Huntsman has donated more than $250 million of his own money since Huntsman Cancer Institute was established. [1] Mary Beckerle is HCI's chief executive officer and director. [2]
This status was further renewed in 2010, and gained its new designation as an NCI-designated Comprehensive Cancer Center in 2015. [2] Only 51 centers in the nation hold this designation. [3] The UNMCCC is the only cancer center in New Mexico designated by the National Cancer Institute (NCI). [4]
The Huntsman Cancer Institute at the University of Utah. One of Huntsman's most notable causes is the Huntsman Cancer Institute (HCI) at the University of Utah, of which he was the founder and principal benefactor. He and his wife Karen established the Huntsman Cancer Institute in 1993 with a gift of $10 million from the Huntsman family.
Cancer centers must renew their status with the NIH every 5 years. The NIH funds cancer centers through a P30 Cancer Center Support Grant (CCSG) mechanism. [2] To be eligible to apply, a cancer center must receive at least $10 million in cancer research funding annually. Preparation for these grant applications can be extensive.
In many developing countries cancer incidence, insofar as this can be measured, appears much lower, most likely because of the higher death rates due to infectious disease or injury. With the increased control over malaria and tuberculosis in some Third World countries, incidence of cancer is expected to rise.
It went public as the Huntsman Corporation on the New York Stock Exchange NYSE: HUN in February 2005. Huntsman has grown through a series of acquisitions (with some divestitures) and today is a manufacturer and marketer of differentiated and specialty chemical products. In April 1994, Huntsman acquired the Texaco Chemical company for $1.1 ...
1900 – Swedish Dr. Stenbeck cures a skin cancer with small doses of radiation [4]; 1920s – Dr. William B. Coley's immunotherapy treatment, regressed tumors in hundreds of cases, the success of Coley's Toxins attracted heavy resistance from his rival and supervisor, Dr. James Ewing, who was an ardent supporter of radiation therapy for cancer.
Mary Beckerle in 2012. Mary C. Beckerle is an American cell biologist who studies cancer at the Huntsman Cancer Institute at the University of Utah School of Medicine.At Huntsman Cancer Institute, she serves as the CEO and also as Associate Vice President for Cancer Affairs at the University of Utah.